Radboud University Medical Center

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

  NCT07357675· Phase 3· EBI Anti Sepsis BV· Source

• Not yet recruiting

  A Phase 1/2/3 Study of ATSN-201 Gene Therapy in Subjects with RS1-Associated X linked Retinoschisis

  NCT05878860· Phase 3· Atsena Therapeutics Inc.· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers

  NCT07609901· Phase 3· Radboud University Medical Center· Source

• Not yet recruiting

  Preventive Dendritic Cell Vaccination for Lynch Syndrome

  NCT07412197· Phase 1/2· Radboud University Medical Center· Source

• Not yet recruiting

  Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma

  NCT07895342· Radboud University Medical Center· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  A Physical Activity Programme Focussed on Step Volume and Intensity for People With Cardiovascular Disease: Getting Active and Staying Active After Cardiac Rehabilitation

  NCT07723274· Radboud University Medical Center· Source

• Recruiting

  Prospective Prostate Cancer Infrastructure

  NCT07560748· Radboud University Medical Center· Source

• Recruiting

  Timing of Immunotherapy in Melanoma

  NCT07696715· Radboud University Medical Center· Source

• Recruiting

  Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)

  NCT07582458· Phase 2/3· Radboud University Medical Center· Source

• Recruiting

  Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma

  NCT07680556· Radboud University Medical Center· Source

• Enrolling by invitation

  Measuring Athlete's Risk of Cardiovascular Events 3 (MARC-3)

  NCT07625488· Radboud University Medical Center· Source

• Not yet recruiting

  Valvosoft Outcomes Registry for Real-World Evidence

  NCT07520591· Cardiawave SA· Source

• Recruiting

  KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

  NCT06451757· Phase 3· Khondrion BV· Source

• Not yet recruiting

  Dilated Cardiomyopathy - Unknown Therapeutic Risk Reduction by Contempary Medication and Implantable Cardioverter-Defibrillators (DUTCH-ICD)

  NCT07415642· University Medical Center Groningen· Source

• Enrolling by invitation

  App-based Protein Support for Older Adults; Coaching Towards Healthy Ageing

  NCT07415408· Radboud University Medical Center· Source

• Not yet recruiting

  RAPIDE: The Feasibility of a Hybrid Care Model

  NCT06735404· Radboud University Medical Center· Source

• Recruiting

  Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

  NCT07316296· Phase 3· Radboud University Medical Center· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

  NCT07078383· Vascutek Ltd.· Source

• Recruiting

  A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

  NCT07301034· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas

  NCT07071727· The Netherlands Cancer Institute· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Recruiting

  T3-4-Hypo trial

  2024-513883-24-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

  2024-514693-47-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation

  NCT07200466· Radboud University Medical Center· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  PEEP-induced Effects on Respiratory dRivE and EFfort

  NCT07203781· Radboud University Medical Center· Source

• Recruiting

  Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

  NCT06993142· Radboud University Medical Center· Source

• Recruiting

  Respiratory Muscles in End-stage Lung Disease: Pathophysiological Processes & Clinical Consequences

  NCT06935825· University Medical Center Groningen· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

  NCT06416345· Amsterdam UMC, location VUmc· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Source

• Recruiting

  Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial

  NCT07281508· Phase 3· The Netherlands Cancer Institute· Source

• Recruiting

  SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

  NCT07021495· Leiden University Medical Center· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Rapamycin Holdings Inc.· Source

• Recruiting

  Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

  2023-510356-23-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  SIMBA

  2024-514740-82-00· Phase 4· Stichting Amsterdam UMC· Source

• Recruiting

  A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

  NCT06832722· Phase 1/2· 4TEEN4 Pharmaceuticals GmbH· Source

• Recruiting

  Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

  NCT07145450· Phase 1/2· Anocca AB· Source

• Recruiting

  Master protocol of TCR-modified T cell therapy targeting HLA-restricted KRAS antigen administered in adult patients with metastatic or locally advanced PDAC

  2024-513900-32-00· Phase 1/2· Anocca AB· Source

• Recruiting

  Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer

  NCT07046468· Radboud University Medical Center· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  The TASTY-steering Study

  NCT07258563· University Medical Center Groningen· Source

• Recruiting

  Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial

  NCT06805396· Phase 2· Roxanne Gal· Source

• Recruiting

  Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer

  NCT07180381· St. Antonius Hospital· Source

• Active, not recruiting

  Pediatric Expansion Study of the Sentio System

  NCT06976086· Oticon Medical· Source

Showing 50 of 223.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease14 recruiting
• Prostate cancer12 recruiting
• Lung cancer11 recruiting
• Childhood cancers9 recruiting
• Colorectal cancer9 recruiting
• Bladder cancer7 recruiting
• Gastric and oesophageal cancer7 recruiting
• Parkinson disease7 recruiting
• Pancreatic cancer6 recruiting
• Crohn's disease5 recruiting
• Head and neck cancer5 recruiting
• Heart failure5 recruiting
• Sarcoma5 recruiting
• Cervical cancer4 recruiting
• Endometrial cancer4 recruiting
• Hearing loss4 recruiting
• Liver and biliary tract cancer4 recruiting
• Ovarian cancer4 recruiting
• Stroke4 recruiting
• Ulcerative colitis4 recruiting
• Aortic aneurysm3 recruiting
• Duchenne muscular dystrophy3 recruiting
• Melanoma3 recruiting
• Obesity3 recruiting
• Aortic stenosis2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometriosis2 recruiting
• High blood pressure2 recruiting
• Hypothyroidism2 recruiting
• Metastatic breast cancer2 recruiting
• Retinitis pigmentosa2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Barrett's oesophagus1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Congenital heart disease1 recruiting
• COPD1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Dilated cardiomyopathy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Hidradenitis suppurativa1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Triple-negative breast cancer1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II

  NCT06422494· Radboud University Medical Center· Source

• Completed

  A Study to Assess TTI-0102 vs Placebo in MELAS Patients

  NCT06644534· Phase 2· Thiogenesis Therapeutics, Inc.· Source

• Completed

  A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors

  2022-502367-37-00· Phase 1/2· Novartis Pharma AG· Source

• Terminated

  Home Monitoring in Hemophilia A

  NCT06702579· Radboud University Medical Center· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Completed

  The Influence of Artificial Intelligence (AI )Assisted Polyp Detection (Discovery System) on Visual Gaze Patterns During Real-time Colonoscopy

  NCT05619614· Radboud University Medical Center· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Completed

  A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

  NCT06131398· Phase 1· Amgen· Source

• Completed

  MItochondrial Diabetes LOw Carb- Diet Study

  NCT06185790· Radboud University Medical Center· Source

• Completed

  STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases

  2023-505721-13-00· Phase 2· University Hospital Maastricht· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer

  NCT05724602· Phase 2· European Organisation For Research And Treatment Of Cancer· Source

• Completed

  Rivaroxaban Sotorasib Interaction Study

  NCT06314763· Phase 4· Radboud University Medical Center· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

  NCT05938270· Phase 1· AstraZeneca· Source

• Completed

  Assessment of Diagnostic Yield Using a Robotic Navigational Bronchoscopy System With CBCT

  NCT06084208· Intuitive Surgical· Source

• Completed

  Remote 3-week Booster Intervention to Reduce Sedentary Time in Patients With Coronary Artey Disease

  NCT06038188· Radboud University Medical Center· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

  NCT05952869· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Safety and Effectiveness of Intermittent Hypoxia Treatment in Parkinson's Disease

  NCT05948761· Phase 1/2· Radboud University Medical Center· Source

• Completed

  A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)

  2024-512390-27-00· Phase 1· Byondis B.V.· Source

• Completed

  OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

  NCT05972954· Phase 2· Omeicos Therapeutics GmbH· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease

  NCT05596201· Radboud University Medical Center· Source

• Completed

  The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study

  NCT05723406· Phase 2· Radboud University Medical Center· Source

• Recruiting

  NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

  NCT05773859· Phase 1/2· Radboud University Medical Center· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers

  NCT05648201· Phase 4· Radboud University Medical Center· Source

• Completed

  Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed

  NCT05642481· Radboud University Medical Center· Source

• Recruiting

  High-Risk prostatE Cancer radiatiOn Versus surgERy

  NCT05931419· Comprehensive Cancer Centre The Netherlands· Source

• Completed

  An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease

  NCT05543252· Phase 2· UCB Biopharma· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma

  NCT05507775· Radboud University Medical Center· Source

• Completed

  Upper Extremity Versus Lower Extremity Accessory Access Sites During Transcatheter Aortic Valve Implantation

  NCT05672823· Radboud University Medical Center· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Sanofi· Source

• Completed

  Time Restricted Eating and Innate Immunity

  NCT05639244· Radboud University Medical Center· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

  NCT05776459· Phase 2· AudioCure Pharma GmbH· Source

• Completed

  Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC

  NCT05555199· Radboud University Medical Center· Source

• Completed

  The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study

  NCT05712603· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

  NCT05491616· Phase 2· Erasmus Medical Center· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Completed

  Trained Immunity in Thyroid Carcinoma and Colon Carcinoma

  NCT05280379· Radboud University Medical Center· Source

• Completed

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease

  2023-504412-14-00· Phase 1· F. Hoffmann-La Roche AG· Source

• Completed

  First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  2023-508357-58-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

  NCT05258071· Phase 2· Integrative Research Laboratories AB· Source

Showing 50 of 123.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke147 works · 12 trials
• Parkinson disease110 works · 19 trials
• Prostate cancer100 works · 32 trials
• Coronary artery disease74 works · 29 trials
• Tuberculosis62 works · 1 trial
• Atrial fibrillation50 works · 3 trials
• Psoriasis38 works · 4 trials
• Systemic sclerosis (scleroderma)36 works · 4 trials
• Ovarian cancer35 works · 11 trials
• Depression31 works · 1 trial
• Pancreatic cancer29 works · 13 trials
• Sarcoma29 works · 8 trials
• Type 1 diabetes25 works · 3 trials
• Kidney cancer25 works · 3 trials
• Hearing loss24 works · 10 trials
• Autism23 works · 0 trials
• Rheumatoid arthritis22 works · 0 trials
• Atopic dermatitis (eczema)20 works · 2 trials
• Aortic stenosis19 works · 7 trials
• Spinal cord injury17 works · 0 trials
• Endometrial cancer16 works · 8 trials
• Macular degeneration16 works · 3 trials
• Retinitis pigmentosa15 works · 5 trials
• Childhood cancers14 works · 13 trials
• Haemophilia13 works · 3 trials
• Thyroid cancer12 works · 2 trials
• Ankylosing spondylitis11 works · 0 trials
• Endometriosis11 works · 3 trials
• Huntington's disease11 works · 0 trials
• Aortic aneurysm11 works · 4 trials